Literature DB >> 12218091

Cutting edge: myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection.

Heike Weighardt1, Simone Kaiser-Moore, Ramunas M Vabulas, Carsten J Kirschning, Hermann Wagner, Bernhard Holzmann.   

Abstract

Toll-like receptors (TLRs) are important for the activation of innate immune cells upon encounter of microbial pathogens. The present study investigated the potential roles of TLR2, TLR4, and the signaling protein myeloid differentiation factor 88 (MyD88) in polymicrobial septic peritonitis. Whereas both TLR2 and TLR4 were dispensable for host defense against septic peritonitis, MyD88-deficient mice were protected in this infection model. Recruitment of neutrophils to the septic focus and bacterial clearance were normal in MyD88-deficient mice. In contrast, the systemic inflammatory response was strongly attenuated in the absence of MyD88. Surprisingly, MyD88 deficiency did not alter cytokine and chemokine production in spleen, but markedly reduced the inflammatory response in liver and lung. Production of monocyte chemoattractant protein-1 and macrophage-inflammatory protein-1alpha was entirely independent of MyD88. These results imply a central role of MyD88 for the systemic immune pathology of polymicrobial sepsis and show that cytokine production in spleen and induction of certain chemokines are MyD88 independent.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218091     DOI: 10.4049/jimmunol.169.6.2823

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  Dominant role of the MyD88-dependent signaling pathway in mediating early endotoxin-induced murine ileus.

Authors:  Bettina M Buchholz; Timothy R Billiar; Anthony J Bauer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-05-27       Impact factor: 4.052

Review 2.  Differential Paradigms in Animal Models of Sepsis.

Authors:  S Manoj Kumar Kingsley; B Vishnu Bhat
Journal:  Curr Infect Dis Rep       Date:  2016-09       Impact factor: 3.725

Review 3.  The role of Toll-like receptors in renal diseases.

Authors:  Anna Gluba; Maciej Banach; Simon Hannam; Dimitri P Mikhailidis; Agata Sakowicz; Jacek Rysz
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

Review 4.  Current and future concepts of abdominal sepsis.

Authors:  Klaus Emmanuel; Heike Weighardt; Holger Bartels; Jorg-Rudiger Siewert; Bernhard Holzmann
Journal:  World J Surg       Date:  2005-01       Impact factor: 3.352

5.  Toll-like receptor 2 is required for inflammatory responses to Francisella tularensis LVS.

Authors:  Jannet Katz; Ping Zhang; Michael Martin; Stefanie N Vogel; Suzanne M Michalek
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 6.  Modeling sepsis in the laboratory: merging sound science with animal well-being.

Authors:  Jean A Nemzek; Kelly M S Hugunin; Mark R Opp
Journal:  Comp Med       Date:  2008-04       Impact factor: 0.982

7.  Aberrant inflammatory response to Streptococcus pyogenes in mice lacking myeloid differentiation factor 88.

Authors:  Torsten G Loof; Oliver Goldmann; André Gessner; Heiko Herwald; Eva Medina
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

8.  Differential expression of Toll-like receptors 2 and 4 in tissues of the human female reproductive tract.

Authors:  Patricia A Pioli; Eyal Amiel; Todd M Schaefer; John E Connolly; Charles R Wira; Paul M Guyre
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

9.  MyD88 is necessary for neutrophil recruitment in hypersensitivity pneumonitis.

Authors:  Stephanie C Nance; Ae-Kyung Yi; Fabio C Re; Elizabeth A Fitzpatrick
Journal:  J Leukoc Biol       Date:  2008-02-19       Impact factor: 4.962

10.  Type I interferon signaling in hematopoietic cells is required for survival in mouse polymicrobial sepsis by regulating CXCL10.

Authors:  Kindra M Kelly-Scumpia; Philip O Scumpia; Matthew J Delano; Jason S Weinstein; Alex G Cuenca; James L Wynn; Lyle L Moldawer
Journal:  J Exp Med       Date:  2010-01-13       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.